SCHEMBL7143696

SCHEMBL7143696

CCCCCCc1cc2c(cc1C=O)C(C)(C)CCC2(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 8/20 0.43
HIF1A Q16665 1/20 0.35
EPAS1 Q99814 1/20 0.35
LIPG Q9Y5X9 1/20 0.34
GPR84 Q9NQS5 8/20 0.34
RARA P10276 1/20 0.34
RARB P10826 1/20 0.34
RARG P13631 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
PPARG P37231 1/20 0.34
NR1H3 Q13133 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX5 P09917 1/20 0.33
MAPT P10636 1/20 0.33
TYR P14679 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143276 0.98 RXRA (0.43) RXRAHIF1AEPAS1GPR84RARA
SCHEMBL9054943 0.88 RXRA (0.48) RXRARARARARBRARGRXRB
SCHEMBL8905381 0.85 RXRA (0.40) RXRAGPR84RARARARBRARG
SCHEMBL8905375 0.85 RXRA (0.40) RXRALIPGGPR84RARARARB
SCHEMBL8906033 0.85 RXRA (0.40) RXRALIPGGPR84RARARARB
SCHEMBL8906045 0.85 RXRA (0.40) RXRAGPR84RARARARBRARG
SCHEMBL5947942 0.82 RXRA (0.44) RXRARARARARBRARGRXRB
SCHEMBL28429565 0.81 HIF1A (0.44) HIF1AEPAS1LIPGGPR84MEN1
SCHEMBL28428038 0.81 HIF1A (0.44) HIF1AEPAS1LIPGGPR84MEN1
SCHEMBL7088782 0.81 HIF1A (0.44) HIF1AEPAS1LIPGGPR84MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610877-B1 Treating photo and/or age damaged skin HOFFMAN-LA ROCHE INC. 2003-08-26 US disclosed
EP-1301505-A2 THIOPHENE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-16 EP disclosed
US-6403810-B2 RESPIRATORY SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2002-06-11 US disclosed
US-20020019438-A1 Thiophene derivatives F. HOFFMANN-LA ROCHE AG (CH) 2002-02-14 US disclosed
WO-2002004439-A2 THIOPHENE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 WO disclosed
EP-0641759-B1 Use of aromatic carboxylic derivatives for the preparation of drugs HOFFMANN LA ROCHE (CH) 1998-12-09 EP disclosed
US-5700836-A TOPICALLY ADMINISTERING TO TREAT PHOTODAMAGED SKIN HOFFMANN-LA ROCHE INC. (US) 1997-12-23 US disclosed
EP-0641759-A1 Aromatic carboxylic acid derivatives, their preparation and drugs containing these derivatives F. HOFFMANN-LA ROCHE AG (CH) 1995-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019438-A1 Thiophene derivatives RARG, RARA, RARB RXRA 4/4885HIF1A 1134/4885EPAS1 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.